Julia Neugebauer

USPTO Granted Patents = 13 (Patent Applications = 3)

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 6 (Patent Applications = 6)

Average Co-Inventor Count = 4.6

ph-index = 3

Forward Citations = 24(Granted Patents)

Location History:

München, DE (2012)
Munich, DE (2016 - 2024)

Company Filing History:

Years Active: 2012-2024

Loading Chart...

13 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12054555 - Anti-BAFFR antibody formulations and methods of use thereof (2024-08-06),

2. 12018072 - Antibodies specific for human complement C5A receptor (C5AR) (2024-06-25),

3. 11542329 - Antibodies targeting Glycoprotein VI (2023-01-03),

4. 11472880 - Humanized antibodies for CD3 (2022-10-18),

5. 11254734 - Fab molecules with a rodent hinge region and a non-rodent CH1 region (2022-02-22),

6. 10899841 - Anti-BAFFR antibody formulations and methods of use thereof (2021-01-26),

7. 9988455 - Methods of treating cardiovascular disorders with lectin-like oxidized LDL receptor 1 antibodies (2018-06-05),

8. 9988443 - Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use (2018-06-05),

9. 9562101 - Lectin-like oxidized LDL receptor 1 antibodies and methods of use (2017-02-07),

10. 9458240 - Anti-BAFFR antibody formulations (2016-10-04),

11. 9382326 - Compositions and methods of use for therapeutic antibodies (2016-07-05),

12. 9340620 - Compositions and methods of use for therapeutic antibodies (2016-05-17),

13. 8106163 - Compositions and methods of use for therapeutic antibodies (2012-01-31),

Title: Innovations by Julia Neugebauer

Introduction

Julia Neugebauer is a prominent inventor based in Munich, Germany. She has made significant contributions to the field of biotechnology, particularly in the development of antibody formulations. With a total of 13 patents to her name, Neugebauer's work has the potential to impact the treatment of various diseases.

Latest Patents

Among her latest patents is the development of Anti-BAFFR antibody formulations and methods of use thereof. These antibodies are formulated as either lyophilisate or liquid formulations. The lyophilisates can be reconstituted to create a solution with a high concentration of the antibody active ingredient, allowing for effective delivery to patients without high levels of antibody aggregation. Additionally, the lyophilisate can be reconstituted with an aqueous reconstituent to provide an aqueous composition with an antibody concentration of at least 50 mg/ml. This composition may include various components such as sugars, buffering agents, surfactants, and free amino acids. Another significant patent involves antibodies specific for the human complement C5A receptor (C5AR). This invention provides novel antibodies or antibody fragments that specifically bind to human C5aR, which are useful for treating inflammatory or autoimmune diseases or cancer.

Career Highlights

Julia Neugebauer has worked with notable companies in the biotechnology sector, including Novartis AG and MorphoSys AG. Her experience in these organizations has contributed to her expertise in antibody development and formulation.

Collaborations

Throughout her career, Neugebauer has collaborated with esteemed colleagues such as Stefanie Urlinger and Christoph Heusser. These collaborations have further enhanced her research and development efforts in the field of biotechnology.

Conclusion

Julia Neugebauer's innovative work in antibody formulations and her extensive patent portfolio highlight her significant contributions to biotechnology. Her inventions have the potential to advance treatments for various diseases, showcasing her impact on the industry.

This text is generated by artificial intelligence and may not be accurate.